TY - JOUR
T1 - Impaired glutamate homeostasis in the nucleus accumbens in human cocaine addiction
AU - Engeli, Etna J.E.
AU - Zoelch, Niklaus
AU - Hock, Andreas
AU - Nordt, Carlos
AU - Hulka, Lea M.
AU - Kirschner, Matthias
AU - Scheidegger, Milan
AU - Esposito, Fabrizio
AU - Baumgartner, Markus R.
AU - Henning, Anke
AU - Seifritz, Erich
AU - Quednow, Boris B.
AU - Herdener, Marcus
N1 - Funding Information:
Acknowledgements We thank Johanna Klar, Nathalie Rieser, Martina Riva, and Colette Steinegger for assistance in data collection and Katrin Preller for support with questionnaire programming. This project was supported by a grant from the Zurich Center for Integrative Human Physiology, University of Zurich.
Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/9
Y1 - 2021/9
N2 - Cocaine addiction is characterized by overwhelming craving for the substance, which drives its escalating use despite adverse consequences. Animal models suggest a disrupted glutamate homeostasis in the nucleus accumbens to underlie addiction-like behavior. After chronic administration of cocaine, rodents show decreased levels of accumbal glutamate, whereas drug-seeking reinstatement is associated with enhanced glutamatergic transmission. However, due to technical obstacles, the role of disturbed glutamate homeostasis for cocaine addiction in humans remains only partially understood, and accordingly, no approved pharmacotherapy exists. Here, we applied a tailored proton magnetic resonance spectroscopy protocol that allows glutamate quantification within the human nucleus accumbens. We found significantly reduced basal glutamate concentrations in the nucleus accumbens in cocaine-addicted (N = 26) compared with healthy individuals (N = 30), and increased glutamate levels during cue-induced craving in cocaine-addicted individuals compared with baseline. These glutamatergic alterations, however, could not be significantly modulated by a short-term challenge of N-acetylcysteine (2400 mg/day on 2 days). Taken together, our findings reveal a disturbed accumbal glutamate homeostasis as a key neurometabolic feature of cocaine addiction also in humans. Therefore, we suggest the glutamatergic system as a promising target for the development of novel pharmacotherapies, and in addition, as a potential biomarker for a personalized medicine approach in addiction.
AB - Cocaine addiction is characterized by overwhelming craving for the substance, which drives its escalating use despite adverse consequences. Animal models suggest a disrupted glutamate homeostasis in the nucleus accumbens to underlie addiction-like behavior. After chronic administration of cocaine, rodents show decreased levels of accumbal glutamate, whereas drug-seeking reinstatement is associated with enhanced glutamatergic transmission. However, due to technical obstacles, the role of disturbed glutamate homeostasis for cocaine addiction in humans remains only partially understood, and accordingly, no approved pharmacotherapy exists. Here, we applied a tailored proton magnetic resonance spectroscopy protocol that allows glutamate quantification within the human nucleus accumbens. We found significantly reduced basal glutamate concentrations in the nucleus accumbens in cocaine-addicted (N = 26) compared with healthy individuals (N = 30), and increased glutamate levels during cue-induced craving in cocaine-addicted individuals compared with baseline. These glutamatergic alterations, however, could not be significantly modulated by a short-term challenge of N-acetylcysteine (2400 mg/day on 2 days). Taken together, our findings reveal a disturbed accumbal glutamate homeostasis as a key neurometabolic feature of cocaine addiction also in humans. Therefore, we suggest the glutamatergic system as a promising target for the development of novel pharmacotherapies, and in addition, as a potential biomarker for a personalized medicine approach in addiction.
UR - http://www.scopus.com/inward/record.url?scp=85087026491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087026491&partnerID=8YFLogxK
U2 - 10.1038/s41380-020-0828-z
DO - 10.1038/s41380-020-0828-z
M3 - Article
C2 - 32601455
AN - SCOPUS:85087026491
SN - 1359-4184
VL - 26
SP - 5277
EP - 5285
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 9
ER -